Navigation Links
Breast Health Study Advances Safety Profile for Soy-Based Natural S-equol Supplement Designed to Manage Menopause Symptoms
Date:9/13/2011

NORTHRIDGE, Calif., Sept. 13, 2011 /PRNewswire/ -- Consuming the soy germ-based compound Natural S-equol and the supplement SE5-OH containing Natural S-equol did not increase the risk of estrogen-sensitive breast cancer, according to a study in the September issue of the peer-reviewed journal Food and Chemical Toxicology.  SE5-OH containing Natural S-equol reduced menopause symptoms in postmenopausal women in previously reported controlled trials in the United States and in Japan.

"A major concern of health care professionals and women in managing menopausal symptoms is that a treatment might increase the risk of developing or progressing breast cancer," said Belinda H. Jenks, Ph.D., Director of Scientific Affairs & Nutrition Education at Pharmavite LLC, the makers of Nature Made® vitamins and minerals and a subsidiary of Otsuka Pharmaceutical Co., Ltd., which supported the study. "This study is the first to directly examine the effects of Natural S-equol alone and SE5-OH containing Natural S-equol, which we are developing to reduce menopause symptoms, directly on the growth of human breast cancer cells in an established mouse model as well as in directly in cell cultures. The study documented that Natural S-equol itself, as well as SE5-OH, did not increase or stimulate the growth of these breast cancer cells."

The safety of SE5-OH containing Natural S-equol previously was confirmed by standard animal testing.  Also, studies involving postmenopausal women who consumed SE5-OH containing Natural S-equol have not observed any safety problems, including analysis of breast and reproductive tissues and of hormone levels, and have documented significant reductions in hot flashes frequency, in muscle and joint discomfort. More information about S-equol and SE5-OH, including study results, is at http://www.naturalequol.com.

S-equol [7-hydroxy-3-(4'-hydroxyphenyl)-chroman] is a compound resulting -- when certain bacteria are present in the digestive tract -- from the natural metabolism, or conversion, of daidzein, an isoflavone found in whole soybeans.  Not everyone can produce S-equol after soy consumption, as the production depends on the types of bacteria present in the large intestine and may be influenced by the amount of soy consumed. About 50 percent of Asians and 20 to 30 percent of North Americans and Europeans, who in general consume less soy than Asians, have the ability to produce high levels of S-equol naturally.  Preliminary evidence from observational studies suggests that among Japanese women, those who produce S-equol naturally may have fewer menopausal symptoms.  Controlled clinical trials have documented that a supplement containing Natural S-equol reduces the frequency of hot flashes as well as muscle discomfort associated with menopause, both in Japan and the United States.

"S-equol binds to the same estrogen receptors as naturally occurring, endogenous estrogen, but with a stronger affinity for the estrogen beta receptor.  Because of the actions that S-equol has that mimic some but not all activities of naturally occurring estrogen, it is important for us to explore the effects of S-equol as well as of SE5-OH containing Natural S-equol on human breast cancer cells," explains Jenks.

About 60 to 70 percent of human breast cancers are estrogen-positive, in which estrogen, the main sex hormone in women, acts with high affinity to these receptors and increases the number of cancer cells.

Breast Cancer Tumor Not Influenced by Natural S-equol
No significant differences in the size of human breast tumors occurred between mice that ate diets for 25 weeks containing Natural S-equol, SE5-OH, genistein (an isoflavone that occurs naturally in soy) or a soy-free diet.

For the study, investigators implanted 71 healthy female mice - from which the ovaries had been surgically removed - with pellets containing 2 milligrams (mg) of 17-beta estradiol, a form of estrogen.  One week later, the researchers injected the mice with MCF-7-E10 cells, which are estrogen-dependent, human breast cancer cells that have both alpha and beta estrogen receptors.  When the cells had grown to tumors that averaged 34 square millimeters in size, nine of the mice continued unaltered, as a control, while the rest of the mice had their estrogen pellets removed.

The 62 mice without estrogen then received one of four diets daily for 25 weeks: either 250 or 500 parts-per-million (ppm) of the soy isoflavone genistein, SE5-OH or purified S-equol or no soy isoflavones.  The researchers measured the size of the implanted tumors, total body weight and food intake weekly.

At 25 weeks, the tumor sizes did not significantly differ and for the 250 or 500 ppm groups, respectively, averaged 61 square millimeters in the estrogen pellet-free control group, 96 and 79 square millimeters in the genistein groups, 65 and 80 square millimeters in the SE5-OH groups, and 62 and 56 square millimeters in the S-equol groups.  In comparison, by week 10, the mice had estrogen pellets had tumors that averaged 269 +/- 72.1 square millimeters.

In other studies, doses of the supplement SE5-OH containing Natural S-equol ranging from 10 to 30 mg daily were effective in reducing menopausal symptoms without significant adverse events.

Laboratory tests on MCF-7-E10 cells and Estrogen Receptors
In tests using laboratory cultures of MCF-7-E10 cells, Natural S-equol and SE5-OH containing Natural S-equol did not stimulate estrogen receptor activity or the multiplication of MCF-7-E10 cells unless given at concentrations that were 10,000 to one million times larger than the levels needed to induce comparable activity with 17-beta estradiol (0.05 +/- 0.00 to 0.16 +/- 0.13 pico moles,).

Authors of the study are Atsuko Onoda, M.S., Tomomi Ueno, M.S., and Shigeto Uchiyama, M.S. of Otsuka Pharmaceutical Co, LTD, Saga, Japan; and Kiyoko Kato, Ph.D., M.D., and Norio Wake, Ph.D., M.D., of the Department of Obstetrics and Gynecology at the Graduate School of Medical Sciences of Kyushu University, Fukuoka, Japan.  An initial report on the study data was presented in a poster at the Women's Health Congress 2011 in April.

How SE5-OH Ingredient is Made
SE5-OH is the product of fermentation of whole soy germ by the bacterial strain Lactococcus 20-92 using a patented and proprietary process by the Otsuka Pharmaceutical Co., Ltd.  The process results in the conversion of the daidzein to Natural S-equol.  SE5-OH is created under current Good Manufacturing Practices.  Following fermentation, the bacteria undergo heat denaturation and are deactivated.  The process is designed to produce a Natural S-equol rich product, or nutraceutical ingredient.  The ingredient has self-affirmed GRAS (Generally Recognized As Safe) status.

Development and ongoing research of SE5-OH containing Natural S-equol is conducted by the Saga Nutraceuticals Research Institute of Otsuka Pharmaceutical Co., Ltd.

About Pharmavite LLC:  For 40 years, Pharmavite has earned and maintained the trust of healthcare professionals, consumers, and retailers by manufacturing high-quality vitamins, minerals, herbs and other dietary supplements that are safe, effective and science-based.  Nature Made® is the number one selling dietary supplement brand in the food, drug, club and mass channels.  The dietary supplement industry is regulated by the U.S. Food and Drug Administration and the Federal Trade Commission, as well as by government agencies in each of the 50 states.

About Otsuka Pharmaceutical Co., Ltd.:  Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health.  Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment.  Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group has business operations in 23 countries and regions around the world, with consolidated sales of 1,090.2 billion Yen for fiscal year 2010.  Visit Otsuka Pharmaceutical Co., Ltd. at http://www.otsuka.co.jp/en/.


'/>"/>
SOURCE Pharmavite LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
2. Naviscan Receives CE Mark Approval for High-Resolution Breast PET and PET-Guided Biopsy
3. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
4. SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona
5. Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
6. International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
7. SIUH Offers New 5-Day Breast Cancer Therapy
8. Siemens Partners with American Cancer Society to Make Strides Against Breast Cancer
9. Medela Announces 2011 Breastfeeding Hall of Excellence Inductees to Nationally Recognize Exceptional Breastfeeding Advocates
10. Evergreen Hospital Launches Revolutionary Breast Cancer Detection and Diagnostic Imaging Technology
11. A Simple Way to Detect Breast Cancer at Stage 0 Discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, ... The global anti-obesity drugs market is expected ... of the forecast period and CAGR of 38.7% in the second ... at a CAGR of 32.8% from 2016 to 2027. The market ... and $24,063 million in 2027. ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 Accuray ... its CyberKnife® and TomoTherapy® Systems continue to set the ... received the highest composite overall user satisfaction rating among ... the Q4 2016 MD Buyline Market Intelligence Briefing™. The ... the highest composite ratings among industry peers for 11 ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) officials today announced a ... the Network’s programs and services in the greater Pittsburgh region. Starting January 23, patients ... offered one for that same afternoon. , AHN is the first ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... asset protection and financial planning services to communities throughout eastern Georgia, is embarking ... against heart disease. , Heart disease kills more Americans every year than anything ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or ...
(Date:1/19/2017)... ... ... Attorney Robert “RC” Pate , founder of The Law Office of ... Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. In 2006, ... of the critical funding gap for research into pediatric cancer research. From 2006 onwards, ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second ... Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. ... have each been chosen by their peers for the 2017 list based on ...
Breaking Medicine News(10 mins):